[Management of invasive fungal infections in pediatric patient].
Among children, an epidemiologic shift has caused an increase in non-albicans Candida infections and invasive aspergillosis, as well as infections by pathogens that were previously uncommon. These infections are frequent causes of infectious morbidity in immunocompromised children. Treatment options are limited for children. When choosing a therapy, it is important to consider pivotal clinical trial data, available pediatric pharmacokinetic profiles, safety and drug interactions profiles, and species-dependent susceptibilities. For most infections, the best initial treatment is still unassessed. Caspofungin is not yet approved for pediatric use, but an ongoing clinical program on this field gives promising results.
Groll
A
A
D'après la communication.
D000293:Adolescent; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077336:Caspofungin; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D019468:Disease Management; D017277:Drug Approval; D054714:Echinocandins / Q000627:therapeutic use; D016469:Fungemia / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D055666:Lipopeptides
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin